Statins are associated with only a very small increase in risk of diabetes mellitus. Previous research selected the outcomes with the lower baseline risks and therefore the actual risk associated with statins has been largely over-estimated.
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INTRODUCTION
Statins are used extensively to reduce low-density lipoprotein cholesterol and have been associated with significant benefits in patients with coronary artery disease, including a reduced risk of myocardial infarction, stroke, and death (1) . Several trials have recently demonstrated that these benefits are greater with an intensive statin regimen which has been shown to reduce the risk of cardiovascular events and death beyond that of the standard (moderate dose) statin regimen (2; 3). However, there is growing concern that the protective properties of statins may be offset by non-cardiovascular safety concerns and moreover, that this risk of adverse events may also be greater with intensive-dose statin therapy compared with a standard regimen (2) .
The main adverse event of concern is the previous suggestion that statin therapy can be associated with approximately a nine percent higher risk of developing diabetes mellitus compared with placebo or standard care (4) (5) (6) , and this risk appears to be dose dependent (7) .
A meta-analysis by Preiss et al. compared intensive-dose with moderate-dose statin therapy and reported a 12% increase in the odds (OR=1.12) of incident diabetes among patients assigned to intensive-dose statin therapy compared with a standard dose (7). Our concern was that these risks may have been magnified by the mathematical peculiarity whereby the odds ratios (ORs) and relative risks (RRs) are inflated when event rates are low (8) . We therefore undertook the present study to re-analyse the meta-analysis by Preiss et al. utilising the complementary outcome of non-events for which the event rates were higher, and provide clarification with regards to the safety implications of statin treatment.
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METHODS
Five randomised controlled trials (RCTs) that compared the risk of diabetes onset with intensive-dose and moderate-dose statin therapy were included in the replication of the meta-analysis by Preiss et al. (7) .The event of interest was redefined as the complementary outcome with the higher baseline risk, which was no-onset of diabetes. In selecting the outcome with the higher baseline risks, the mathematical anomaly by which the RRs are magnified at lower baseline risks was avoided (8) . In addition, the RRs were reported rather than the ORs as the effect size of the intervention because magnification occurs at both ends of the risk spectrum for the OR while it only arises at the lower end of the risk spectrum for the RR (8).
The risk difference (RD) at two years follow-up was also computed by estimating the events based on the yearly incidence rate of the complementary outcome in each RCT. For these studies of duration more than two years, the yearly incidence rate (IR) was estimated as
where CI t is the cumulative incidence proportion of events at the end of the study and t is the duration of follow-up (9). The two year cumulative incidence was then computed as (2) 1 IR e − − . In addition to the RD, the number needed to harm (NNH) and the number needed to treat (NNT) were computed based on the computed RD at two years.
Heterogeneity was considered present if tau squared ( I are derived from Cochran's Q and thus these indices mostly concur albeit with varying degrees of sensitivity. The RCTs included were found to be homogeneous, thus the fixed effects model (inverse variance) was used to pool the effect estimates. This however is identical to the random effects model used by Preiss et al. (7) given the lack of heterogeneity across studies. The analysis was done using MetaXL version 1.4 (http://www.epigear.com). Table 1 presents the number of non-events (no-onset of diabetes) from the five RCTs. 
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RESULTS
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In absolute terms, the differences between the intervention and control groups for the statin analyses were statistically significant. One more patient is harmed by diabetes onset for every 237 patients exposed to intensive-dose statin therapy over two years compared to the moderate dose strategy. Given that the treatment effect in terms of cardiovascular prevention in previously reported studies is large (14; 15) and statin intervention has been well documented to reduce cardiovascular events and prevent death (16) , this benefit will not be offset by the very small risk of onset of diabetes.
It is clear based on the results that reclassification of the event as the outcome with higher baseline risk (no-onset of diabetes) has put the RR into perspective and thus avoided the mathematical exaggeration of the RR that occurs with lower baseline risks (8) .
Nevertheless, there is still a risk documented, albeit small. This warrants further research to determine the mechanism of this effect so that patients at risk can be identified and offered alternative therapies. The issue of reporting a falsely exaggerated magnitude of the RR (due to the incorrect selection of the outcome with the smaller baseline risks) goes beyond the statin therapy that we have addressed in this publication. Similarly to the case presented in which the side effect of a drug is falsely magnified, the beneficial effects of a drug can also be falsely exaggerated; therefore, we believe that not only the RR for the outcome with the higher baseline risks should be reported but also an absolute measurement of association (NNT/NNH) should be reported mandatorily. M A N U S C R I P T NOTE. The number of events was computed based on the yearly incidence rate and the NNH is reported at 2 years.
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